A Critical Analysis of the Role of Testosterone in Erectile Function: From Pathophysiology to Treatment—A Systematic Review

Andrea M. Isidori, Jacques Buvat, Giovanni Corona, Irwin Goldstein, Emmanuele A. Jannini, Andrea Lenz, Hartmut Pors, Andrea Saloni, Abdulmaged M. Traish, Mario Maggi

a Sapienza University of Rome, Rome, Italy; b Centre ETPARP, Lille, France; c Maggiore-Bellaria Hospital, Bologna, Italy; d Alvarado Hospital, San Diego, CA, USA; e University of L'Aquila, L'Aquila, Italy; f Private Urological/Andrological Practice, Hamburg, Germany; g University Vita-Salute San Raffaele, Milan, Italy; h Boston University School of Medicine, Boston, MA, USA; i University of Florence, Florence, Italy

Abstract

Context: Androgen modulation of erectile function (EF) is widely accepted. However, the use of testosterone replacement therapy (TRT) in men with erectile dysfunction (ED) has generated an unprecedented debate.

Objective: To summarize the relevant data on the incidence, diagnosis, and management of ED coexisting with hypogonadism and to develop a pathophysiology-based treatment algorithm.

Evidence acquisition: We reviewed the relevant medical literature, with a particular emphasis on original molecular studies, prospective observational data, and randomized controlled trials performed in the past 20 yr.

Evidence synthesis: Testosterone modulates nearly every component involved in EF, from pelvic ganglions to smooth muscle and the endothelial cells of the corpora cavernosa. It also regulates the timing of the erectile process as a function of sexual desire, coordinating penile erection with sex. Epidemiologic studies confirm the significant overlap of hypogonadism and ED; however, most guidelines do not consider the differential diagnosis of hypogonadism or the relevance of subclinical disease. Various clinical tools can help the physician to assess and restore androgen levels in men with ED. Special attention is given to fertility-sparing treatments, due to the increasing number of older men desiring fatherhood. The simultaneous use of phosphodiesterase type 5 inhibitors (PDE5-Is) and TRT has recently been questioned. Originally proposed as a salvage therapy for nonresponders to PDE5-Is, this approach has been inappropriately transformed into a combination therapy. Clinical data are consistent when reinterpreted in the proper framework, whereas molecular evidence remains controversial.

Conclusions: A body of molecular and clinical evidence supports the use of TRT in hypogonadal patients with ED, although the benefit–risk ratio is uncertain in advanced age. Critical appraisal of this evidence enabled the development of a pathophysiology-oriented algorithm designed to avoid inappropriate treatments and support whether to start with TRT, PDE5-I only, or both. Apparently divergent findings are reconciled when TRT is correctly indicated. An improved diagnosis and individualized management is desirable in light of the many available options.
1. **Introduction**

Erectile dysfunction (ED) has emerged as an important marker of cardiovascular (CV) and overall health, independently of other known conventional risk factors [1]. Normal sexual activity throughout the adult lifespan has been associated with a reduced incidence of CV events, suggesting a protective role [2]. Coronary artery disease is preceded by ED in half of the affected subjects, underlining the need for proper screening [3]. Sexual dysfunction is the most specific symptom of late-onset hypogonadism (LOH) [4] in the aging man, a condition also associated with an increased mortality for CV events [5]. However, ED still remains largely underdiagnosed and untreated. The Global Study of Sexual Attitudes and Behavior showed that <30% of men with ED had sought medical help, due to high social and personal barriers [6].

Public awareness of the benefits of phosphodiesterase type 5 inhibitors (PDE5-Is) has significantly shortened the time lag between the onset of ED and the seeking of medical help [7]. The same cannot be said for testosterone replacement therapy (TRT) in LOH, despite the availability of excellent multifaceted treatment options, due to the long-standing controversies surrounding safety versus efficacy in male sexual dysfunction. The scientific community is sharply divided into those for or against TRT, with a proliferation of studies with apparently contradictory findings, generating a debate without comparison in any other hormone deficiency.

These considerations prompted us to perform a critical appraisal of the major studies of TRT in sexual dysfunction, focusing on three of the critical questions: (1) Is TRT worthwhile in ED patients? If so, how and when? (2) Does testosterone (T) act centrally or peripherally? (3) What are the underlying facts and beliefs about the combination of T and PDE5-I therapy? Is it safe?

2. **Evidence acquisition**

We reviewed the relevant medical literature, with a particular emphasis on original molecular studies, prospective observational data, and randomized controlled trials (RCTs) performed in past 20 yr that included the search terms testosterone or hypogonadism and erectile function (EF). We provide a systematic review and critical appraisal of the data (see Supplement).

3. **Evidence synthesis**

3.1. **Hormonal assessment in erectile dysfunction patients**

The European Male Ageing Study (EMAS) found that 30% of European men experienced ED and two-thirds of them were eugonadal [4]. In representative samples, the prevalence of hypogonadism ranges between 23% and 36% of ED subjects [8] and varies according to the cut-off value adopted for the diagnosis, respectively 7%, 23%, 33%, or 47% for T levels of <7, 10.4, 12, or 14 nmol/l [9]. These figures, however, are simple associations that do not imply any causal association between the two conditions.

Detractors of universal screening of androgen deficiency in ED subjects point out that, in addition to the known causes of hypogonadism (Fig. 1), the frequent real or...
spurious fluctuations in T levels produce several false diagnoses. Drugs could also affect T levels (see Supplemental Table 1). A transient drop in T could be due to acute illness, and no lower limit of normal is universally accepted. There is, however, general agreement that total T and no lower limit of normal is universally accepted. There is, however, general agreement that total T >12 nmol/l (>350 ng/dl) does not require replacement therapy, whereas T <8 nmol/l does eventually merit treatment. The strength of this consensus is inversely proportional to the age of the subjects, so replacement therapy for a baseline T of 10 nmol/l would gain more support in a 40-yr-old man than in a 70-yr-old man. Table 1 provides suggestions on how to assess gonadal status in ED patients. A second confirmation of a reduced T level is highly recommended, possibly including measurement of sex hormone-binding globulin (SHBG), to enable the calculation of free testosterone (fT) [10]. Prolactin should also be assessed in all cases of reduced T values [11].

Surprisingly, most guidelines do not consider the differential diagnosis of the cause of hypogonadism to be mandatory in the diagnosis of LOH; as a consequence, luteinizing hormone (LH) measurement is often considered unnecessary [10,12]. This oddity is justified by the very high frequency of a mixed etiology, with an altered hypothalamic-pituitary-gonadal (HPG) feedback loop secondary to age, comorbidities, and drugs. Measuring LH could be useful not only for the diagnosis of primary hypogonadism (low T and elevated LH), often associated with sexual symptoms, but also to identify “compensated” or “subclinical” hypogonadism [13,14].

The latter condition is characterized by normal or low-normal T (gray zone) and elevated LH (>9.4 U/l). This subgroup of subjects, whose number steadily increases with age, is the largest in the elderly. In addition, young men with Klinefelter syndrome, the most common numerical chromosomal aberration (47, XXY), affecting 0.2% of the male population (www.uroweb.org/guidelines) [10], often have subclinical hypogonadism that later in life becomes overt primary hypogonadism [15]. The latter cannot be dismissed as “functional” and is not the consequence of acute illnesses. Like primary hypogonadism, it is strongly associated with physical and sexual symptoms, indicating that when T declines from a previously high-normal to a low-normal level, the high LH becomes a biomarker for insufficient androgenization. The finding of elevated LH thus reinforces the need to consider replacement therapy, although clinical trials in this subgroup are scarce, and the data on long-term follow-up are only recently emerging. Conversely, a very low T in the presence of normal/low LH may indicate a pituitary tumor, even with a normal prolactin, and requires pituitary imaging [11].

3.2. Molecular evidence for testosterone dependency of penile structure, growth, and responsiveness

It is generally accepted that androgens modulate erectile physiology in humans and animals. Although most of the animal data are derived from androgen ablation from surgical castration and gonadotropin-releasing hormone (GnRH) analogs, a model that can hardly be transferred to ED in humans, at least one study used, as an experimental model, hypogonadism induced by a high-fat diet, and the findings were consistent with the reports from castration studies [16]. Three levels are under T control: the central nervous system (CNS) nuclei, the spinal motoneurons, and the genital tissues (Fig. 2). The CNS effects of androgens are complex, mainly exerted on the release of stimulatory neurotransmitters such as dopamine, oxytocin, and nitric oxide (NO), controlling sexual dimorphic development and mating behaviors [17]. At peripheral levels, androgens modulate nearly every component involved in EF: structure, function, and innervation of trabecular smooth muscle cells, endothelial function of penile vessels, and fibroelastic properties of the corpus cavernosum. However, the molecular pathways involved are far from understood. In addition, part of the erectile response to T is centrally mediated, through an effect on sexual desire, and this dichotomy has split researchers, with some supporting a predominance of the central over the peripheral sites of action. Finally, animal studies have shown species-specific differences and were performed after castration, a model very different from hypogonadism in men, generating uncertainty that is further complicated by the paucity of available human data.

3.2.1. The nitric oxide and adrenergic pathways

Most animal studies agree that castration caused a rapid drop in intracavernous pressure due to both reduced arterial inflow and altered veno-occlusion during stimulated erections [18]. In rats, castration is associated with a
rapid reduction in neuronal nitric oxide synthase (nNOS) activity [19] and pelvic ganglion activity [20]. This is almost completely reversed by NO, suggesting that NO generation is a major acute effector of androgens (Fig. 2). However, reports of nNOS response differ significantly, with some studies showing an increased activity in rats but no change in protein expression [19] and others showing no effect in rabbits [21]. Studies performed in L-NAME–treated animals (a nitric oxide synthase [NOS] inhibitor), revealed some additional mechanisms involved in the androgen regulation of EF. Interestingly, this NO-independent mechanism still appears to require cyclic guanosine monophosphate (cGMP) generation, critical to both NO-independent and NO-dependent pathways [22].

Non-NO–mediated androgenic effects seem to be exerted mainly on the veno-occlusion mechanism.

Sensitivity to neurotransmitters is another possible target of androgens (Fig. 2). In rats, castration appears to increase the α1-adrenergic responsiveness of the cavernosal smooth muscle cells [23]. Surprisingly, in rabbits the α1-adrenergic receptors seem to be downregulated by castration and restored by androgen replacement [21]. Castration in rats is also associated with a decreased density of nonadrenergic-noncholinergic (NANC) innervating fibers and reduced NANC-mediated relaxation in isolated corpus cavernosum strips, but again, not in rabbits, confirming interspecies differences [21]. In summary, nNOS activity seems to be the major target of androgens [19,20], followed by opposite regulation of NANC and α1-adrenergic signaling [21].

3.2.3. Penile innervation and structure

The data just presented suggest that a major effect of T is on the postganglionic parasympathetic neurons, or even further upstream, within the autonomic nervous system (Fig. 2). A more complex pelvic neuronal activity is supported by the fact that the effects of castration on penile hemodynamics, including NOS activity, can be transiently reversed in vivo by short-term electrical stimulation of the cavernosal nerve [19]. Most studies agree that castration produces changes in...
the critical balance between trabecular smooth muscle and connective tissue. Androgen deprivation results in programmed trabecular smooth muscle cell death (apoptosis) and an increase in the extracellular matrix [21]. Androgen deprivation is also associated with the accumulation of fat-containing cells (fibroblasts or preadipocyte-like cells), especially in the subtunical region of the corpus cavernosum, thus contributing to impaired veno-occlusion [29]. According to the neuronal circuitry hypothesis, the main role of androgens is to support the adequate neuronal stimulation of the corpora cavernosa, also necessary to maintain tissue structural integrity and the differentiation of penile mesenchymal stem cells. The latter hypothesis is supported by the similarities between penile fibrotic changes developing after castration, in animals, and those after denervation following prostate surgery, in men.

In humans, T influences penile development, mainly as a result of extracellular stromal expansion [30]. Postnatal penile length and growth rate also seem to be correlated with the T surge occurring in the first 3 mo of life (mini-puberty) [31]. However, no further correlation is seen in postpubertal adults. Most studies agree that androgen sensitivity and androgen receptor expression vary with age and stage of penile development. Whether or not this mechanism is primarily regulated by androgens remains controversial. The few human studies failed to document this feedback, suggesting that penile growth cessation after puberty depends on other, nonandrogen-dependent mechanisms [30]. Thus androgens seem necessary to maintain the fibroelastic properties of penile tissues, at least in animal models [19,21,29]. Studies in humans suggest that androgens are also involved in prepubertal penile growth [30,31], although other independent mechanisms control growth cessation [30].

3.2.4. 5α-reductase inhibitors and erectile function
Following a proliferation of studies in the 1990s, interest in androgen action in penile physiology gradually diminished. However, attention has been renewed by the discovery that a group of young subjects developed persistent diminished libido and ED as a consequence of early exposure to 5α-reductase inhibitors (5-ARIs) [32]. This condition, termed postfinasteride syndrome, seemed to occur in a small, but not insignificant, subgroup of young subjects who had taken a 5-ARI for alopecia (although similar symptoms can also develop in patients taking a 5-ARI for benign prostatic hyperplasia). The severity of symptoms seems to correlate to an early intake at the end of pubertal development, at a stage when the effects of androgenic activity are still peaking. The 5-ARI transforms not only T but also other metabolites that can in turn be converted into a subclass of neuroactive steroids with distinct physiologic actions.

In animal models, 5-ARIs have been associated with reduced EF, with marked structural and functional alterations in penile tissue contributing to penile fibrosis that is mainly exerted through a modulation of cholinergic and adrenergic sensitivity, with no apparent change in PDE-5 [33]. The depressive symptoms developed by 5-ARI users who experienced sexual dysfunction are consistent with former animal studies showing that androgenic regulation of sexual activity is partially controlled through a modulation of reflexes of social behaviors [34] that goes well beyond libido. It is also known that different androgen thresholds are necessary to activate copulatory behavior and penile reflexes in rats, which are significantly increased in animals prenatally exposed to alcohol, stress, or endocrine disruptors [35]. The hypothesis of a dynamic reset of central threshold values could explain, at least in part, the androgen insensitivity of aging men chronically exposed to drugs and diseases.

3.3. Association between testosterone and erectile function in men
Most animal studies suffer from a short observational period following castration and androgen administration, which may influence nerve and tissue remodeling. Conversely, most human studies are cross sectional and show divergent results. Some describe a significant association of androgens with various measures of EF [36,37]; others do not [38]. Most of the early studies were retrospective, underpowered, uncontrolled for comorbidities, body mass index, and SHBG, and weak on the methods used to assay hormones. The recent EMAS study, a sufficiently large prospective study using mass spectrometry, shed some light on this controversial issue [39]. The study found that total T is significantly associated with overall sexual function, and fT with ED and masturbation frequency, independently of 17β-estradiol (E₂) or dihydrotestosterone. More importantly, it identified a cutoff of 8 nmol/L above which any further increase in circulating T lost any positive correlation.

These findings are in line with previous studies showing, in a human model of endogenous T suppression by GnRH agonists, a dose response consistent with the existence of a T threshold effect [40], and others showing that variation of T levels within the normal range had no effects on sexual function [41]. However, some authors have pointed out that hypogonadal men may have near-normal sexual activity [37]. Overall, dose–response studies seem to suggest that the androgen dependency of EF is maintained at threshold values far below those required to maintain the function of other target organs. This has been demonstrated in otherwise healthy men with low T, but it does not automatically translate to elderly men with comorbidities, in whom these thresholds may be reset.

The EMAS study also showed that E₂, but not T, correlated with the psychological symptoms of male aging, confirming the findings of Basar et al. [42]; both these studies found a robust independent correlation between E₂ and sexual dysfunction–associated distress. Another study found that T was associated with somatized anxiety only in the older men with ED [36]. These aspects are most novel in light of the recently introduced concept of compensated or subclinical hypogonadism [13] (Fig. 1). In fact, subclinical hypogonadism is also strongly associated with physical and sexual symptoms, indicating that when T in men declines from a previously high-normal to a low-normal level, the
high LH becomes a biomarker for insufficient androgenization [13,14].

3.4. Effects of treating erectile dysfunction in hypogonadal men using testosterone

Normal men probably have more androgens than are necessary, in the short term, for normal sexual activity. Acute, complete androgen withdrawal is unequivocally associated with loss of sexual interest and erectile failure. These symptoms are promptly reversed by the administration of a small amount of T. In the 1980s, Bancroft and Wu performed the pivotal studies to discriminate central versus peripheral effects, demonstrating that in acute settings, erectile capacity in response to visual stimulation is less sensitive to androgen than is sexual interest, fantasies, and cognitive sexual activities [43].

Several clinical trials documented a significant improvement in erections and sexual function in hypogonadal men [44–47]. Uniquely among hormone replacement studies, the non–placebo-controlled trials are often dismissed as not evidence based. The few available RCTs were reviewed in three distinct meta-analyses showing a large effect of TRT on libido in men with reduced androgen levels, and a small effect on sexual satisfaction and various parameters of EF in men with low to normal T levels [48,49]. The first one reports the positive effect of TRT on EF in men with mean T levels <10 nmol/l (standardized mean difference [SMD]: 1.8; 95% confidence interval [CI], 0.31–3.43) [48]. In a subsequent one, Bolona et al. [49] found a small yet significant effect (SMD: 0.34; 95% CI, 0.03–0.65) on EF of men with low-normal T levels, and a greater effect in the subgroup of young subjects (SMD: 1.80; 95% CI, 1.0–2.7), emphasizing a role of aging as a possible moderator of ED responsiveness to TRT. In particular, a nonsignificant effect was found in older men. In the last available meta-analysis, Tserstvadze et al. [8] concluded that results of any TRT were inconsistent regarding their effects on EF, degree of erection, or improved erection. Due to these contrasting results, we systematically analyzed all the data available so far concerning RCTs, reported in the Supplement (Supplemental Table 2).

The 20 identified RCTs showed large discrepancies in clinical response, with individual variations related to bias in the studies, age, type, and potency of T preparation, outcome measures, and comorbidities of the recruited subjects. No effect was found in men with T >12 nmol/l, whereas in 10 of the 14 RCTs performed in hypogonadal men, a beneficial effect of TRT on EF was found. Among studies providing crude International Index of Erectile Function (IIEF) data [45,46,50–53], TRT produced a weighted mean improvement of baseline IIEF score of 39% (range: 22–79%) corresponding to a weighted mean delta of IIEF-5 of 4.32 ± 2.01 points (range: 3–8). The European Association of Urology (EAU) guidelines for male sexual dysfunction gave a level of evidence (LE) of 1b (at least one RCT) and a grade of recommendation (GR) of B (based on well-conducted but not randomized trials) to the need to treat at first any “curable cause of ED” including hypogonadism [12]. The EAU guidelines on hypogonadism gave an LE of 3 (based on well-designed and nonexperimental studies) and a GR of B the opportunity to treat “decreased libido and erection” with testosterone [10].

Another relevant aspect that has only recently received attention is the time course of T effects (ie, the length of treatment necessary to achieve the maximum result). A systematic analysis showed effects on libido, ejaculation, and sexual activity within just 2–3 wk, whereas effects on EF may require up to 6 mo to become detectable by IIEF [54]. Recent RCTs showed that a statistically significant improvement in IIEF, detectable at 6 mo as marginal changes [46,47], can achieve a further significant increase after 12 mo of an open-label treatment [45,46]. Taken into account these limitations, the time course of TRT has been claimed to explain some negative findings in the experimental human studies on T/sex thresholds that were mainly performed in the acute settings (weeks), as opposed to penile tissue recovery that may require several months.

Few studies have explored whether there is any difference between raising T by exogenous steroid administration or by Leydig cell stimulation. This is more relevant in view of the increasing proportion of aging men with ED who still wish to achieve fatherhood. Buvat showed that raising T by human chorionic gonadotropin (hCG) is associated with an increase in sexual activity in half of men with normal baseline T levels [55].

Guay [56] showed that the normalization of androgens by clomiphene produced a satisfactory response in 39% of all treated men, with younger subjects (<55 yr) responding better than older men and men with comorbidities. One of the most interesting findings was that pituitary stimulation in secondary hypogonadism, even if related to acute or chronic illness, can be used transiently while the underlying problem is corrected. In addition, a recent study showed that clomiphene citrate is also safe and effective for the long-term management of male hypogonadism [57], making it suitable for men seeking fertility. Alternatively, the adjunct of low-dose hCG to TRT prevents spermatogenesis suppression and can be used in impotent hypogonadal men in whom fertility remains an issue [58] (Fig. 3).

To summarize, increasing androgen levels, either by hormonal replacement [8;45–53] (Supplemental Table 2) or by the stimulation of Leydig cells [55–57] is superior to placebo in improving various sexual outcomes, but the magnitude and timing of effects [45,46,54] are highly variable and difficult to predict. To improve the response, a combined treatment could also be considered (Fig. 3). On the contrary, when baseline T levels are normal, no beneficial effects has to be expected from TRT.

3.5. Effects of treating erectile dysfunction in hypogonadal men using a phosphodiesterase type 5 inhibitor

PDE5-Is are rapid and potent drugs acting directly on the mechanisms of erection, and they have changed the expectation of both physicians and patients about how to improve EF. The fact that sexual activity per se can affect T levels has been hypothesized since the 1970s. However, the first formal studies by Jannini and colleagues showed that restoring EF by nonhormonal therapies (eg, psychotherapy,
intracavernous injections) in various settings can raise circulating T by 30–40% of baseline values [59]. The same effect was subsequently demonstrated with PDE5-I therapy [60]. An attempt was made to investigate whether this was a drug-specific effect. However, the increase in the frequency of sexual intercourse, by whatever means this was achieved, was the best predictor of androgen recovery [59,60]. This finding was confirmed in a large RCT, which found that a 4-wk run-in of PDE5-I in hypogonadal men significantly raised T levels by a mean of 4 nmol/l [61].

The consequences of being unable to achieve full penetration are thought to be the major cause for down-regulation of the neurohormonal mechanism that controls the GnRH pulse generator and in such patients causes hypogonadism [13]. However, recent studies show that PDE5 is expressed by Leydig cells and its inhibition can increase hormone release [27], suggesting that a direct testicular action is also possible. Based on the available studies, the increase in T that can be expected after PDE5-I use is in the range of 3–6 nmol/l [59,61]. These data support a possible role of PDE5-I as the sole treatment in selected men presenting with ED and reduced T levels (Fig. 3). However, the use of only a PDE5-I may be insufficient in other cases: A young man with severe hypotestosteronemia is unlikely to restore eugonadism simply by increasing his sexual performances with a PDE5-I. In addition, given the proposed mechanisms, subjects with an elevated LH are unlikely to respond to a PDE5-I, given that the feedback is already enhanced and Leydig cells might be dysfunctional.

3.6. Effects of combining testosterone and phosphodiesterase type 5 inhibitor

Combination therapy with PDE5-I and T is highly debated, with strong reasons in favor or against it asserted by the various researchers. PDE5-Is are effective, but regardless of their pharmacokinetics or the regimen used, none have been shown to cure ED. Thus they remain symptomatic drugs [60]. In hypogonadal men, PDE5-Is alone might be sufficient to improve erections, but they are inadequate to address all domains of sexual function and the systemic complication of hypogonadism (Fig. 3). Epidemiologic studies show that sexual dysfunction is one of the main symptoms causing hypogonadal men to seek medical help [4]. For this reason, once treated with PDE5-Is, they may no longer be interested in correcting their underlying androgen deficiency. Symptomatic pro-erectile treatment will thus leave such men otherwise untreated and exposed to a greater risk of osteoporosis, diabetes, dyslipidemia, obesity, and CV morbidity and mortality [62].

Although PDE5-I may effectively treat erections, as measured by the IIEF, they cannot address the ancillary sexual signs and symptoms associated with hypogonadism, such as low libido, reduced ejaculatory volume, and other
symptoms [63]. Therefore, even if erection hardness is tangibly improved, the subject’s sex life may not be fully restored.

3.6.1. Testosterone replacement therapy and phosphodiesterase type 5 inhibitor: “salvage” versus “combination” therapy

The fact that ED and hypogonadism often coexist in aging men led some authors to explore whether the combination of a PDE5-I and TRT would elicit beneficial effects. Originally proposed as “salvage therapy” for nonresponders or PDE5-I failures [64,65], this approach has been improperly transformed into a “combination” therapy, with the aim of adding the beneficial effects of each drug on EF to one another. The post hoc analysis of the TADTEST trial showed that below a threshold of 10.4 nmol/l (300 ng/dl) for total T, the efficacy of PDE5-I is suboptimal [65]. The salvage rate that could be obtained in hypogonadal men, failing a PDE5-I, was highly variable ranging from 32% to 100% [66], with some sort of improvement expected in about two-thirds of treated patients.

However, this approach was recently questioned by a large study from Spitzer and colleagues, designed to address whether TRT has any additional effect when erection score is maximized by a PDE5-I [61]. The study definitively confirmed that there is no need to add T when EF is already being restored by a PDE5-I, other than to treat the systemic complications of hypogonadism. However, the trial was not powered to address any role of T as a salvage therapy because there was a significant increase in T during the sildenafil optimization run-in. This resulted in a large percentage of the study subjects with T >12 nmol/l at randomization, and the overall number of PDE5-I failures was low.

Whether or not TRT should be offered to all men who remain hypogonadal while failing PDE5-I therapy remains debated (Fig. 3). TRT might rescue some of these failures by boosting all aspects of men’s sexual health, including several minor targets, from libido to ejaculation volume and the so-called nonspecific mood-lifting properties. Putative benefits are unlikely to be exerted through an increase in erection hardness, the parameter scored by the IIEF-5, but rather by subtle changes in cavernous smooth muscle cells, libido, motivation, and ejaculation [63] that may also be important, even if not measured by the IIEF. In summary, TRT should be used first in some subgroups of patients, especially in young men with organic hypogonadism, whereas others may benefit from the use of combination therapy from the beginning (Fig. 3). Yet a relevant group of ED hypogonadal patients could safely be started on PDE5-I monotherapy and, in those who retain persistently low T levels, TRT should be offered as a salvage therapy for PDE5-I failure (Fig. 3).

3.7. How and when to increase testosterone levels in erectile dysfunction patients

If the cause of ED is low T, as is often the case in young hypogonadal men, androgen replacement is the cure, and monotherapy often suffices. This can be achieved with the daily administration of any of the several available topical formulations (Table 2). The cutaneous side effects of the latest gels and solutions are insignificant, although they are more common with older patches. Treatment of severe hypogonadism in younger men might require higher doses than those delivered by the standard gel sachets (usually 50 mg). T monitoring is thus highly recommended to achieve the desired level. Formulations in adjustable dispensers are more suitable for dose titration [67]. The recently introduced long-acting T (available in Europe) overcomes the compliance problems associated with daily administration, offering a treatment that is particularly suitable for young men [47]. Administration once every 12–14 wk frees the patient from considering himself abnormal as a daily application would inevitably recall. It also avoids the problems of washing off the gel or the skin irritations associated with sweating of more physically active men. Long-acting T undecanoate injections have been reported as safe and reliable in both young and older subjects [47], but given the uncertainty of the diagnosis, the variability of T measurement, and the unpredictable hematocrit response, it is advisable to first use a 3-mo run-in with a short-acting gel. For men who intend to father children, a number of alternative options are available including clomiphene or β-hCG (Fig. 3).

When ED is not due solely to hypogonadism but also to a concomitant vascular or metabolic disorder, TRT alone is insufficient to restore erection, and PDE5-I use is required. The effects of androgens on erection are in fact slow and progressive [45,46], and they are often imperceptible to the patient if not administered over a long time [54]. Young hypogonadal men in a stable relationship are often eager to wait and see if the effects of testosterone “cure” their erection while benefiting from the spurt in libido, rather than immediately starting a PDE5-I, perceived as a drug for older men. However, those who experience repeated failures or have an unstable relationship may ask for a drug enabling their rapid achievement of erection, thus counteracting their performance anxiety. Cost is another issue. Although considered very safe, TRT requires periodical monitoring of blood parameters (Table 3). This adds to the cost of the T and any PDE5-I. At least hematocrit and prostate-specific antigen (PSA) in addition to T are generally performed at least every 6 mo [10]. One aspect that deserves mention is the issue of the polymorphism of androgen receptor, in particular the length of CAG repeats that affect the efficiency of receptor signaling that account for a significant variability in the thresholds of symptoms and, more importantly, the responsiveness to TRT (see Supplement) [68].

3.8. Proposal of a treatment algorithm

The collected evidence shows that TRT monotherapy restores sexual function in some cases, whereas in others a PDE5-I only improves T levels. The combination of a PDE5-I and TRT has been tested in hypogonadal men not responding to androgens or in those with persistent hypogonadism following PDE5-I failure. A critical appraisal
reveals that the discrepancies among studies are related to inclusion criteria and outcome measures. TRT monotherapy, PDE5-I only, and the combination of the two could all be valid options for different cases of ED coexisting with hypogonadism. To support physicians in the selection of the best treatment strategy, we have developed a multistep treatment algorithm presented in Figure 3.

3.9. Safety issues and future perspectives

The controversies surrounding TRT for ED have been magnified by uncertainty on its safety. The two major concerns are the prostate and the CV system. The mistake of translating the effects of androgen deprivation in advanced prostate cancer (PCa) to the effects of androgen replacement in noncancerous prostate diseases has generated a number of unjustified fears. The saturation model proposed by Morgentaler and Traish [69] finally reconciled both ends of androgen's effects on prostate growth. A survey of most cited guidelines from international societies is reported in Table 4; all statements offer reassurances on the prostate safety of TRT, once contraindications, counseling, and required screening are respected. A collaborative study comparing 3886 men with incidental PCa with 6438 controls from 18 studies concluded that endogenous concentrations of sex hormones are not associated with the risk of PCa [70]. In contrast, growing evidence indicates that androgens exert an anti-inflammatory effect on human prostatic stromal cells. This could be useful in the treatment of lower urinary tract symptoms, possibly in combination with a PDE5-I [28;71].

### Table 2 – Available preparations to treat male hypogonadism

<table>
<thead>
<tr>
<th>Compound</th>
<th>Dosage</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral agents</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T undecanoate</td>
<td>120–240 mg 2–3 times daily</td>
<td>-Oral</td>
<td>-Variable T levels and clinical responses</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-Adjustable dose</td>
<td>-Must be taken with meals containing at least 20 g of lipids</td>
</tr>
<tr>
<td>Intramuscular agents</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testosterone enanthate</td>
<td>250 mg every 2–3 wk</td>
<td>-Low cost</td>
<td>-Wide fluctuations in T levels</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>-Multiple injections</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>-Relative higher risk of polycythemias</td>
</tr>
<tr>
<td>Testosterone cypionate</td>
<td>200 mg every 2–3 wk</td>
<td>-Low cost</td>
<td>-Wide fluctuations in T levels</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>-Multiple injections</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>-Relative higher risk of polycythemias</td>
</tr>
<tr>
<td>T propionate</td>
<td>100 mg every 2 d</td>
<td>-Low cost</td>
<td>-Wide fluctuations in T levels</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>-Multiple injections</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>-Relative higher risk of polycythemias</td>
</tr>
<tr>
<td>T undecanoate in castor oil</td>
<td>1000 mg every 10–14 wk</td>
<td>-Efficient T normalization</td>
<td>-Pain at injection site</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-Long lasting</td>
<td>-Requires injection training</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-Better compliance</td>
<td></td>
</tr>
<tr>
<td>Subcutaneous agents</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgical implants</td>
<td>4/6 200-mg implants lasting up to 6 mo</td>
<td>-Treatment only twice per year</td>
<td>-Placement is invasive</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>-Risk of extrusion and site infections</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>-Requires trained operator</td>
</tr>
<tr>
<td>Controlled release T buccal formulation agents</td>
<td>30 mg 2 times daily</td>
<td>-Oral</td>
<td>-Possible oral irritation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>-Twice-daily dosing</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>-Unpleasant taste</td>
</tr>
<tr>
<td>Transdermal agents</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T patches</td>
<td>5–10 mg 1 daily</td>
<td>-Mimics circadian rhythm</td>
<td>-Skin irritation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-Simple administration</td>
<td>-Daily administration</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>-Noisy/sport/washing issues</td>
</tr>
<tr>
<td>T gel</td>
<td>40–80 mg 1 daily</td>
<td>-Efficient T normalization</td>
<td>-Possible transfer during intimate contact</td>
</tr>
<tr>
<td>1–2%</td>
<td></td>
<td>-Flexible doses</td>
<td>-Daily administration</td>
</tr>
<tr>
<td>Underarm testosterone</td>
<td>60–120 mg 1 daily</td>
<td>-Efficient T normalization</td>
<td>-Possible transfer during intimate contact</td>
</tr>
<tr>
<td>2% solution</td>
<td></td>
<td>-Flexible doses</td>
<td>-Daily administration</td>
</tr>
<tr>
<td>T gel</td>
<td>20.25–81 mg 1 daily</td>
<td>-Efficient T normalization</td>
<td>-Possible transfer during intimate contact</td>
</tr>
<tr>
<td>1.62%</td>
<td></td>
<td>-Flexible doses</td>
<td>-Daily administration</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-Less skin irritation</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>-Lower amount to apply</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T = testosterone.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 3 – Safety monitoring during testosterone replacement therapy

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>3–6 mo</th>
<th>12 mo</th>
<th>Subsequent screening periodicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testosterone</td>
<td>+</td>
<td>+</td>
<td></td>
<td>6–12 mo</td>
</tr>
<tr>
<td>LH/FSH/PRL</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>6–12 mo</td>
</tr>
<tr>
<td>Hematocrit/Hemoglobin</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>6–12 mo</td>
</tr>
<tr>
<td>Glycemia/Lipid profile</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>12 mo</td>
</tr>
<tr>
<td>PSA</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>6–12 mo</td>
</tr>
<tr>
<td>DRE</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>12 mo</td>
</tr>
<tr>
<td>Bone densitometry scan</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>24 mo</td>
</tr>
</tbody>
</table>

DRE = digital rectal examination; FSH = follicular stimulating hormone; LH = luteinizing hormone; PRL = prolactin; PSA = prostate-specific antigen.
### Table 4 – Survey of currently available guidelines, recommendation, and statements addressing prostate safety of testosterone replacement therapy

<table>
<thead>
<tr>
<th>Target population</th>
<th>Issuing society</th>
<th>Year</th>
<th>Statement</th>
<th>Level of evidence</th>
<th>Grade of recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Risk of newly developed prostate cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testosterone deficiency</td>
<td>ISSM [79]</td>
<td>2013</td>
<td>There is no compelling evidence that high baseline endogenous androgens or TRT cause prostate cancer or prostate cancer progression in the noncastrated man.</td>
<td>1a</td>
<td>–</td>
</tr>
<tr>
<td>Male Hypogonadism</td>
<td>EAU [80]</td>
<td>2012</td>
<td>Randomized controlled trials support the hypothesis that TRT does not result in changes in prostatic histology.</td>
<td>1b</td>
<td>–</td>
</tr>
<tr>
<td>Late-onset hypogonadism</td>
<td>ISA, ISSAM, EAU, EAA, ASA [10]</td>
<td>2009</td>
<td>At the present time, there is no conclusive evidence that TRT increases the risk of prostate cancer or BPH. There is also no evidence that T treatment will convert subclinical prostate cancer to clinically detectable prostate cancer.</td>
<td>4</td>
<td>C</td>
</tr>
<tr>
<td><strong>Patients with locally advanced prostate cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testosterone deficiency</td>
<td>ISSM [79]</td>
<td>2013</td>
<td>T therapy is contraindicated in men with clinical evidence of prostate cancer or any prostatic abnormality suspicious of cancer until more evidence of safety is available.</td>
<td>5</td>
<td>C</td>
</tr>
<tr>
<td>Male hypogonadism</td>
<td>Endocrine Society [81]</td>
<td>2010</td>
<td>We recommend against T therapy in patients with prostate cancer.</td>
<td>Low</td>
<td>Strong</td>
</tr>
<tr>
<td>Late-onset hypogonadism</td>
<td>ISA, ISSAM, EAU, EAA, ASA [10]</td>
<td>2009</td>
<td>There is evidence that T can stimulate growth and aggravate symptoms in men with locally advanced and metastatic prostate cancer.</td>
<td>2a</td>
<td>A</td>
</tr>
<tr>
<td><strong>Patients successfully treated for localized prostate cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testosterone deficiency</td>
<td>ISSM [79]</td>
<td>2013</td>
<td>Men successfully treated for prostate cancer and experiencing confirmed, very symptomatic T deficiency may be candidates for TRT, after a prudent interval (depending on the type of cancer treatment), if there is no evidence of residual disease, and if they had an initial tumor contained in the prostate gland that was not high-grade Gleason score. The risks and benefits must be clearly understood by the patient, and the follow-up must be particularly careful.</td>
<td>4</td>
<td>C</td>
</tr>
<tr>
<td>Male hypogonadism</td>
<td>EAU [80]</td>
<td>2012</td>
<td>In patients operated on for localized prostate cancer, TRT should not start before 1 yr of follow-up without PSA recurrence has been completed.</td>
<td>4</td>
<td>B</td>
</tr>
<tr>
<td>Late-onset hypogonadism</td>
<td>ISA, ISSAM, EAU, EAA, ASA [10]</td>
<td>2009</td>
<td>Men successfully treated for prostate cancer and experiencing confirmed symptomatic hypogonadism are potential candidates for TRT after a prudent interval if there is no clinical or laboratory evidence of residual cancer. The risk and benefits must be clearly discussed with and understood by the patient, and the follow-up must be particularly careful.</td>
<td>2b</td>
<td>C</td>
</tr>
<tr>
<td><strong>Patients with severe LUTS due to BPH</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testosterone deficiency</td>
<td>ISSM [79]</td>
<td>2013</td>
<td>Men with severe symptoms of bladder outlet obstruction should not be started on TRT without prior improvement of the comorbid condition.</td>
<td>5</td>
<td>C</td>
</tr>
<tr>
<td>Male hypogonadism</td>
<td>Endocrine Society [81]</td>
<td>2010</td>
<td>We recommend against TRT in patients with severe lower urinary tract symptoms (IPSS &gt;19) due to BPH represent a relative contraindication (there are no compelling data to suggest that T causes exacerbation of LUTS or promotes acute urinary retention). After successful treatment of lower urinary tract obstruction, this contraindication is no longer applicable.</td>
<td>Very low</td>
<td>Weak</td>
</tr>
<tr>
<td>Late-onset hypogonadism</td>
<td>ISA, ISSAM, EAU, EAA, ASA [10]</td>
<td>2009</td>
<td>Severe symptoms of LUTS evident by a high IPSS (≥21) due to BPH represent a relative contraindication (there are no compelling data to suggest that T causes exacerbation of LUTS or promotes acute urinary retention). After successful treatment of lower urinary tract obstruction, this contraindication is no longer applicable.</td>
<td>4</td>
<td>C</td>
</tr>
</tbody>
</table>

ASA = American Society of Andrology; BPH = benign prostatic hyperplasia; EAA = European Academy of Andrology; EAU = European Association of Urology; IPSS = International Prostate Symptom Score; ISA = International Society of Andrology; ISSAM = International Society for the Study of Aging Male; ISSM = International Society for Sexual Medicine; LUTS = lower urinary tract symptoms; PSA = prostate-specific antigen; T = testosterone; TRT = testosterone replacement therapy.

1a = evidence obtained from meta-analysis of randomized trials; 1b/2a = evidence obtained from at least one randomized trial; 4 = evidence obtained from expert committee reports or opinions or clinical experience of respected authorities. A = based on clinical studies of good quality and consistency addressing the specific recommendations and including at least one randomized trial; B = based on well-conducted clinical studies, but without randomized clinical trials; C = made despite the absence of directly applicable clinical studies of good quality.
3.9.1. Testosterone replacement therapy after successful treatment for prostate cancer

ED is a frequent complication of treatment for PCa. A current debate is whether men who have been surgically treated for localized PCa, without evidence of active disease and showing symptoms of T deficiency, can be considered for TRT. The EAU guidelines conclude that “there is limited evidence suggesting that such treatment may not pose an undue risk of prostate cancer (PC) recurrence or progression.” Yet only scarce data are available.

For this reason, we performed a systematic review of published reports (Supplemental Table 3). Among a total of 179 men treated with TRT after radical prostatectomy, only 4 developed a biochemical recurrence (2.2%) within 2 yr of TRT (only 1.1% had a PSA elevation >0.2 ng/ml). Men treated with different modalities, other than radical prostatectomy, showed a higher recurrence rate. Although a statistically significant increase in PSA can be seen in TRT-treated men, independently of risk stratification, in most cases such an increase was not supportive of PCa recurrence. Multivariate analysis revealed that a higher baseline PSA level was the most relevant risk factor for disease progression, whereas Gleason grade, duration of TRT, and level of T achieved during TRT were not prognostic factors. A small consistent beneficial response on EF is reported in the few studies investigating this issue. A larger number reported improvement in energy, mood, and libido. However, the retrospective nature of these reports and the lack of placebo control limit their value.

3.9.2. Testosterone replacement therapy, phosphodiesterase type 5, and the cardiovascular system

Regarding CV safety, although a single study reports increased CV events in elderly men with limited mobility [72], meta-analyses on TRT for ED showed no increased CV risk [48,49]. Similarly, two other meta-analyses on TRT given for reasons other than ED found no significant effect with respect to specific CV outcomes: arrhythmia, coronary bypass surgery, myocardial infarction, and heart failure [73,74]. However, a more recent meta-analysis [75] found a statistically significant increase in “composite” CV-related event (odds ratio: 1.54; 95% CI, 1.09–2.18), as observed in the Testosterone in Older Men trial [72]. These data suggest that TRT is not entirely risk free in older men with a higher composite risk of CV events. In this respect, the increase in hematocrit remains the most significant identified change with an impact on the CV system. These safety warnings contrast with several studies showing that androgens can counteract the features of metabolic syndrome [5], thus determining a considerable reduction in CV risk [62,76]. However, the CV abnormalities seen in hypogonadal men with Klinefelter syndrome (ie, left ventricular diastolic dysfunction) are not entirely reversed by TRT. This suggests that delayed or suboptimal TRT can produce irreversible changes [77] or, alternatively, that cardiac dysfunction is independent of hypogonadism. The need for prompt treatment of the CV abnormalities associated with ED and hypogonadism was demonstrated by Montorsi et al., who found that severe ED precedes coronary artery disease by about 2–3 yr [3]. Finally, recent studies demonstrated that chronic PDE5-I could also be beneficial to counteract cardiac remodeling [78] and lower urinary tract symptoms [71], showing that treating ED could have potential beneficial effects on various organs and systems.

4. Conclusions

All subjects with an organic cause of primary or secondary hypogonadism, especially if young and with a significant drop in T levels, should receive TRT as first-line treatment. Restoration of sleeping/morning erections should be monitored and, if necessary, PDE5-I added. In adults with LOH or any psychological distress, comorbidity, or drug-related marginally reduced T level, a PDE5-I should be administered first in the attempt to restore sexual function, medications affecting sexuality should be discontinued where possible, and finally, but most importantly, any underlying conditions should be treated. Only then, if androgens remain low, should TRT be used in combination therapy (Fig. 3). This three-step approach, depicted in the algorithm, protects against an inappropriate use of these treatments. The EF improvement that can be expected using TRT is small, compared with a PDE5-I, and it may require several months, whereas the composite effects on various sexual domains, including libido, are greater especially in younger men. Based on the current evidence, there are no major safety concerns that limit the use of TRT in middle-age patients benefiting from treatment, not only in terms of sexual life, but also on the several systemic targets of the action of androgens, such as metabolism, bone, and musculature. In older men with proven CV risks, TRT could yield to an increased number of adverse effects, and for this reason treatment should be individually tailored. The 21st century approach to sexual dysfunction must be based on the perspective of men’s health as a whole.

Author contributions: Mario Maggi had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Isidori, Buvat, Corona, Goldstein, Jannini, Lenzi, Porst, Salonia, Traish, Maggi.

Acquisition of data: Isidori, Corona.

Analysis and interpretation of data: Isidori, Buvat, Corona, Goldstein, Jannini, Lenzi, Porst, Salonia, Traish, Maggi.

Drafting of the manuscript: Isidori, Maggi.

Critical revision of the manuscript for important intellectual content: Isidori, Buvat, Corona, Goldstein, Jannini, Lenzi, Porst, Salonia, Traish, Maggi.

Statistical analysis: Isidori, Corona.

Obtaining funding: None.

Administrative, technical, or material support: None.

Supervision: Isidori, Buvat, Corona, Goldstein, Jannini, Lenzi, Porst, Salonia, Traish, Maggi.

Other (specify): None.

Financial disclosures: Mario Maggi certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria,
References


